Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 8Neoplasms 4Prostate Cancer Metastatic 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × XRP6258 × Clear all
NCT01437488 2025-05-04

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Thomas Jefferson University

Phase 2 Completed
14 enrolled 12 charts
Genitourinary

Carcinoma, Transitional Cell

NCT01668459 2018-12-04

CabB1

University Hospital Birmingham NHS Foundation Trust

Phase 2/3 Completed
20 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡